Dr Reddy's Launches Obeda: A New Hope for Diabetes!

Dr Reddy’s Laboratories is diving into the ₹1,446 crore diabetes market with its new generic drug, Obeda! Launched right after semaglutide's patent expired, this injection costs ₹4,200 a month—62% less than the fancy Ozempic. With plans to sell 12 million pens in the first year, they’re aiming for the top in the diabetes game!